|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kaur S, Najm MZ, Khan MA, Akhter N,
Shingatgeri VM, Sikenis M and Sadaf and Aloliqi AA: Drug-resistant
breast cancer: Dwelling the hippo pathway to manage the treatment.
Breast Cancer (Dove Med Press). 13:691–700. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sharma P: Biology and management of
patients with triple-negative breast cancer. Oncologist.
21:1050–1062. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Muramatsu T, Imoto I, Matsui T, Kozaki K,
Haruki S, Sudol M, Shimada Y, Tsuda H, Kawano T and Inazawa J: YAP
is a candidate oncogene for esophageal squamous cell carcinoma.
Carcinogenesis. 32:389–398. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Xiao L, Zhou H, Li XP, Chen J, Fang C, Mao
CX, Cui JJ, Zhang W, Zhou HH, Yin JY and Liu ZQ: MicroRNA-138 acts
as a tumor suppressor in non small cell lung cancer via targeting
YAP1. Oncotarget. 7:40038–40046. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Pu J, Huang Y, Fang Q, Wang J, Li W, Xu Z,
Wu X, Lu Y and Wei H: Hypoxia-induced Fascin-1 upregulation is
regulated by Akt/Rac1 axis and enhances malignant properties of
liver cancer cells via mediating actin cytoskeleton rearrangement
and hippo/YAP activation. Cell Death Discov. 7(385)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Avruch J, Zhou D and Bardeesy N: YAP
oncogene overexpression supercharges colon cancer proliferation.
Cell Cycle. 11:1090–1096. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Lamar JM, Stern P, Liu H, Schindler JW,
Jiang ZG and Hynes RO: The hippo pathway target, YAP, promotes
metastasis through its TEAD-interaction domain. Proc Natl Acad Sci
USA. 109:E2441–2450. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Guo L, Chen Y, Luo J, Zheng J and Shao G:
YAP1 overexpression is associated with poor prognosis of breast
cancer patients and induces breast cancer cell growth by inhibiting
PTEN. FEBS Open Bio. 9:437–445. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhao B, Kim J, Ye X, Lai ZC and Guan KL:
Both TEAD-binding and WW domains are required for the growth
stimulation and oncogenic transformation activity of yes-associated
protein. Cancer Res. 69:1089–1098. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Rigiracciolo DC, Nohata N, Lappano R,
Cirillo F, Talia M, Scordamaglia D, Gutkind JS and Maggiolini M:
IGF-1/IGF-1R/FAK/YAP transduction signaling prompts growth effects
in triple-negative breast cancer (TNBC) cells. Cells.
9(1010)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wu L and Yang X: Targeting the hippo
pathway for breast cancer therapy. Cancers (Basel).
10(422)2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Jaramillo-Rodríguez Y, Cerda-Flores RM,
Ruiz-Ramos R, López-Márquez FC and Calderón-Garcidueñas AL: YAP
expression in normal and neoplastic breast tissue: An
immunohistochemical study. Arch Med Res. 45:223–228.
2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yao CB, Zhou X, Chen CS and Lei QY: The
regulatory mechanisms and functional roles of the hippo signaling
pathway in breast cancer. Yi Chuan. 39:617–629. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Xu X, Zhang M, Xu F and Jiang S: Wnt
signaling in breast cancer: Biological mechanisms, challenges and
opportunities. Mol Cancer. 19(165)2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gan GN and Jimeno A: Emerging from their
burrow: Hedgehog pathway inhibitors for cancer. Expert Opin
Investig Drugs. 25:1153–1166. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Toh TB, Lim JJ and Chow EK: Epigenetics in
cancer stem cells. Mol Cancer. 16(29)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Karamboulas C and Ailles L: Developmental
signaling pathways in cancer stem cells of solid tumors. Biochim
Biophys Acta. 1830:2481–2495. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhang T, Zhou H, Wang K, Wang X, Wang M,
Zhao W, Xi X, Li Y, Cai M, Zhao W, et al: Role, molecular mechanism
and the potential target of breast cancer stem cells in breast
cancer development. Biomed Pharmacother. 147(112616)2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Valenti G, Quinn HM, Heynen GJJE, Lan L,
Holland JD, Vogel R, Wulf-Goldenberg A and Birchmeier W: Cancer
stem cells regulate cancer-associated fibroblasts via activation of
hedgehog signaling in mammary gland tumors. Cancer Res.
77:2134–2147. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Quinn HM, Vogel R, Popp O, Mertins P, Lan
L, Messerschmidt C, Landshammer A, Lisek K, Château-Joubert S,
Marangoni E, et al: YAP and β-catenin cooperate to drive
oncogenesis in basal breast cancer. Cancer Res. 81:2116–2127.
2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tariki M, Dhanyamraju PK, Fendrich V,
Borggrefe T, Feldmann G and Lauth M: The Yes-associated protein
controls the cell density regulation of hedgehog signaling.
Oncogenesis. 3(e112)2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
NCCN: The NCCN breast cancer clinical
practice guidelines in oncology (version 3.2020)[EB/OL]. Fort
Washington: NCCN [2020-03-09], 2020.
|
|
24
|
Li Q, Liu J, Jiang Z and Liu Q: CSCO
breast cancer guideline: Precise, economical and oriental. Sci
China Life Sci. 63:1410–1412. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Xie P, Zhang M, He S, Chen Y, Xing G, Lu
Y, Liu P, Li Y, Wang S, Chai N, et al: The covalent modifier Nedd8
is critical for the activation of Smurf1 ubiquitin ligase in
tumorigenesis. Nat Commun. 5(3733)2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Calvo F, Ege N, Grande-Garcia A, Hooper S,
Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary
E, Charras G and Sahai E: Mechanotransduction and YAP-dependent
matrix remodelling is required for the generation and maintenance
of cancer-associated fibroblasts. Nat Cell Biol. 15:637–646.
2013.PubMed/NCBI View
Article : Google Scholar
|
|
27
|
Yuan M, Tomlinson V, Lara R, Holliday D,
Chelala C, Harada T, Gangeswaran R, Manson-Bishop C, Smith P,
Danovi SA, et al: Yes-associated protein (YAP) functions as a tumor
suppressor in breast. Cell Death Differ. 15:1752–1759.
2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhu C, Li L, Zhang Z, Bi M, Wang H, Su W,
Hernandez K, Liu P, Chen J, Chen M, et al: A non-canonical role of
YAP/TEAD is required for activation of estrogen-regulated enhancers
in breast cancer. Mol Cell. 75:791–806.e8. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Cao L, Yao M, Sasano H, Sun PL and Gao H:
YAP increases response to trastuzumab in HER2-positive breast
cancer by enhancing P73-induced apoptosis. J Cancer. 11:6748–6759.
2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Cao L, Sun PL, Yao M, Jia M and Gao H:
Expression of YES-associated protein (YAP) and its clinical
significance in breast cancer tissues. Hum Pathol. 68:166–174.
2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Jang GB, Kim JY, Cho SD, Park KS, Jung JY,
Lee HY, Hong IS and Nam JS: Blockade of Wnt/β-catenin signaling
suppresses breast cancer metastasis by inhibiting CSC-like
phenotype. Sci Rep. 5(12465)2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chen Y, Shi HY, Stock SR, Stern PH and
Zhang M: Regulation of breast cancer-induced bone lesions by
β-catenin protein signaling. J Biol Chem. 286:42575–42584.
2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yamaguchi H, Chang SS, Hsu JL and Hung MC:
Signaling cross-talk in the resistance to HER family receptor
targeted therapy. Oncogene. 33:1073–1081. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wu Y, Ginther C, Kim J, Mosher N, Chung S,
Slamon D and Vadgama JV: Expression of Wnt3 activates Wnt/β-catenin
pathway and promotes EMT-like phenotype in trastuzumab-resistant
HER2-overexpressing breast cancer cells. Mol Cancer Res.
10:1597–1606. 2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hui M, Cazet A, Nair R, Watkins DN,
O'Toole SA and Swarbrick A: The hedgehog signalling pathway in
breast development, carcinogenesis and cancer therapy. Breast
Cancer Res. 15(203)2013.PubMed/NCBI View
Article : Google Scholar
|
|
36
|
Riobo-Del Galdo NA, Lara Montero Á and
Wertheimer EV: Role of hedgehog signaling in breast cancer:
Pathogenesis and therapeutics. Cells. 8(375)2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Rajurkar M, De Jesus-Monge WE, Driscoll
DR, Appleman VA, Huang H, Cotton JL, Klimstra DS, Zhu LJ, Simin K,
Xu L, et al: The activity of Gli transcription factors is essential
for Kras-induced pancreatic tumorigenesis. Proc Natl Acad Sci USA.
109:E1038–E1047. 2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Benvenuto M, Masuelli L, De Smaele E,
Fantini M, Mattera R, Cucchi D, Bonanno E, Di Stefano E, Frajese
GV, Orlandi A, et al: In vitro and in vivo inhibition of breast
cancer cell growth by targeting the Hedgehog/GLI pathway with SMO
(GDC-0449) or GLI (GANT-61) inhibitors. Oncotarget. 7:9250–9270.
2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Doheny D, Sirkisoon S, Carpenter RL,
Aguayo NR, Regua AT, Anguelov M, Manore SG, Arrigo A, Jalboush SA,
Wong GL, et al: Combined inhibition of JAK2-STAT3 and
SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor
growth, and metastasis. Oncogene. 39:6589–6605. 2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Stathis A, Hess D, von Moos R, Homicsko K,
Griguolo G, Joerger M, Mark M, Ackermann CJ, Allegrini S, Catapano
CV, et al: Phase I trial of the oral smoothened inhibitor sonidegib
in combination with paclitaxel in patients with advanced solid
tumors. Invest New Drugs. 35:766–772. 2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Garcia N, Ulin M, Al-Hendy A and Yang Q:
The role of hedgehog pathway in female cancers. J Cancer Sci Clin
Ther. 4:487–498. 2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zheng X, Han H, Liu GP, Ma YX, Pan RL,
Sang LJ, Li RH, Yang LJ, Marks JR, Wang W and Lin A: LncRNA wires
up hippo and hedgehog signaling to reprogramme glucose metabolism.
EMBO J. 36:3325–3335. 2017.PubMed/NCBI View Article : Google Scholar
|
